Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Divi's Laboratories and Laurus Labs lead India's record CRDMO growth, Jefferies says

BUZZ-Divi's Laboratories and Laurus Labs lead India's record CRDMO growth, Jefferies says

** Laurus Labs LAUL.NS and Divi's Laboratories DIVI.NS post CRDMO revenue growth of 86% and 50%, respectively, driven by strong execution and commercial manufacturing, the brokerage says, Jefferies says

** India's contract research and drug-making sector delivers record Q2 growth, with CRDMO revenue rising 31% year-on-year, Jefferies says

** Jefferies keeps DIVI's as its top pick and sees peptides as a key long-term growth opportunity

** Brokerage rates DIVI at "buy" with 12,550 rupees PT, while LAUL rated "hold" with 2,100 rupees PT

** Seven of nine covered companies beat expectations, supported by healthy client demand and order execution, the brokerage adds

** Management commentary remains upbeat on order visibility and client demand, Jefferies says

** DIVI up 72.5% YTD vs LAUL' 14% gain



(Reporting by Kashish Tandon in Bengaluru)

((Kashish.tandon@thomsonreuters.com))

Recent news on Divi's Laboratories

See all news